---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-146014"
form_type: "8-K"
ticker: null
cik: "0001785345"
company_name: "Landos Biopharma, Inc."
filed_at: "2024-05-23T23:59:59+00:00"
generated_at: "2026-06-01T09:17:52.943998+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbbVie completes acquisition of Landos Biopharma for $20.42/share plus CVR up to $11.14

## Summary
- Aggregate closing cash consideration ~$137.5M; Landos shareholders receive $20.42 per share in cash plus one CVR per share.
- CVR entitles holders to up to $11.14 in cash upon initiation of first Phase 3 trial of NX-13 for ulcerative colitis by March 31, 2029.
- Landos' lead asset NX-13 is a first-in-class oral NLRX1 agonist in Phase 2 for moderate to severe UC (NEXUS study).
- Landos' directors resigned and CEO/executive officers left; company becomes wholly owned subsidiary of AbbVie.
- Landos common stock to be delisted from Nasdaq before market open on May 24, 2024.

## SEC filing metadata
- accession: 0001193125-24-146014
- form_type: 8-K
- cik: 0001785345
- company_name: Landos Biopharma, Inc.
- filed_at: 2024-05-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785345/000119312524146014/0001193125-24-146014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785345/000119312524146014/d815685d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-146014
- JSON: https://secwatch.observer/filing/0001193125-24-146014.json
- Plain text: https://secwatch.observer/filing/0001193125-24-146014.txt

## Key facts
- M&A Transactions
  Landos Biopharma, Inc. underwent a change of control involving AbbVie Inc. for $20.42 per share, plus one non-tradable contingent value right per share with a value of up to $11.14 per share (closed 2024-05-23).
  - Action: change of control
  - Counterparty: AbbVie Inc.
  - Consideration: $20.42 per share, plus one non-tradable contingent value right per share with a value of up to $11.14 per share
  - Closing: 2024-05-23
  source text: AbbVie has acquired Landos at a price of $20.42 per share, plus one non-tradable contingent value right per share with a value of up to $11.14 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785345/000119312524146014/0001193125-24-146014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.